FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia Clinical Impact Jun 8 Written By Frances Benson https://crisprtx.com/about-us/press-releases-and-presentations/fda-accepts-biologics-license-applications-for-exagamglogene-autotemcel-exa-cel-for-severe-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia 2023 Frances Benson
FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia Clinical Impact Jun 8 Written By Frances Benson https://crisprtx.com/about-us/press-releases-and-presentations/fda-accepts-biologics-license-applications-for-exagamglogene-autotemcel-exa-cel-for-severe-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia 2023 Frances Benson
